Review of epidermal growth factor receptor-tyrosine kinase inhibitors administration to non-small-cell lung cancer patients undergoing hemodialysis

Figure 3 Pharmacokinetics of erlotinib in patients undergoing hemodialysis and those with normal renal function. A: The C_max of erlotinib was 2290 ± 840 ng/mL in patients with NRF. For the patients undergoing HD, the C_max was 1638 ± 206 ng/mL on day 8 and 1638 ± 206 ng/mL on day 9 (after steady state). The C_max was similar in patients with NRF and undergoing HD; B: The plasma concentrations of erlotinib were similar before and after HD; C: The AUC_0-24 was 35760 ± 15720 ng· hr/mL in patients with NRF. For the patients undergoing HD, the AUC_0-24 was 23285 ± 5338 ng· hr/mL on day 8 and 25895 ± 7747 ng· hr/mL on day 9. The AUC_0-24 was similar in patients with NRF and undergoing HD. AUC_0-24: Area under the curve of the plasma concentration from 0 to 24 h; C_max: Maxium concentration; C_trough: Trough concentration; HD: Hemodialysis; NRF: Normal renal function.